A point-of-care conduction device may provide accurate measurements of nerve amplitude potential and conduction velocity for the diagnosis of polyneuropathy in older patients.
Privigen is stabilized with proline, which has been shown to reduce IgG aggregation and dimer formation.
Long-term treatment with opioids is associated with more adverse outcomes in patients with polyneuropathy, including depression, overdose, and opioid dependence.
Polyneuropathy may increase the likelihood of patients receiving long-term opioid therapy.
Researchers identified 3 subgroups of patients with peripheral neuropathic pain, based on sensory signs and symptoms.
Diabetes, prediabetes, and obesity may be metabolic drivers of polyneuropathy.
Clinical Pain Advisor Articles
- Replacing Sleep, Sedentary Behavior With Physical Activity Beneficial in Knee Osteoarthritis
- FDA Outlines Plan for New Analgesic Guidance to Combat Opioid Crisis
- Rheumatologist-Assessed vs Criteria for Inflammatory Back Pain in Psoriatic Arthritis
- Rates of Concurrent Opioid, Sedative-Hypnotic Prescription Fills in Veterans
- Perioperative Pain Management in Patients With Opioid Use Disorder
- Ketamine: Mechanisms of Action, Uses in Pain Medicine, and Side Effects
- Medicinal Cannabis May Not Have Opioid-Sparing Effects in Chronic Noncancer Pain
- Cannabis May Be Effective for Migraine Treatment
- Chronic Neck Pain: Generators, Clinical Examination, MRI Findings, and Differential Diagnosis
- Should Drug Testing Be Implemented Before Prescribing Opioids and Benzodiazepines?
- Dexmedetomidine May Prolong Analgesia Duration in Nerve Blocks
- Reviewing the Efficacy of Intrathecal Morphine, Ziconotide for Cancer- and Noncancer Chronic Pain
- Cochrane Data Release and the Case for Open Science
- Pretreatment With Sumatriptan Can Reduce Cilostazol-Induced Headaches
- Effects of Pain, Depression, and Insomnia on Health Care Use in Older Adults With Osteoarthritis